Akari Therapeutics, Plc (AKTX) /
The profitability of Akari Therapeutics, Plc over the past 10 years
Chart Akari Therapeutics, Plc: operating income, net income, fiscal 2016–2025 Open the chart →Akari Therapeutics, Plc reported a net loss of $17.3M in fiscal 2025, the latest fiscal year on file. That year it had an operating loss of $17.27M. It reported a loss in all 10 years shown.
Year by year
| Fiscal year | Operating income | Net income |
|---|---|---|
| 2025ended Dec 31, 2025 | -$17.27M | -$17.3M |
| 2024ended Dec 31, 2024 | -$21.64M | -$19.79M |
| 2023ended Dec 31, 2023 | -$16.81M | -$10.01M |
| 2022ended Dec 31, 2022 | -$11.85M | -$17.75M |
| 2021ended Dec 31, 2021 | -$17.21M | -$17.42M |
| 2020ended Dec 31, 2020 | -$17.98M | -$17.08M |
| 2019ended Dec 31, 2019 | -$16.96M | -$16.85M |
| 2018ended Dec 31, 2018 | -$20.79M | -$20.5M |
| 2017ended Dec 31, 2017 | -$37.78M | -$35.4M |
| 2016ended Dec 31, 2016 | -$27.25M | -$18.14M |
Fiscal years as Akari Therapeutics, Plc reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Akari Therapeutics, Plc
- The cash flow of Akari Therapeutics, Plc
- The debt of Akari Therapeutics, Plc
- All of Akari Therapeutics, Plc's financials, charted
Companies of a similar size
- TSLATesla, Inc.
- LLYELI LILLY AND COMPANY
- AVGOBroadcom Inc.
- MUMicron Technology, Inc.
- METAMeta Platforms, Inc.
Not investment advice. This page shows what Akari Therapeutics, Plc filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.